Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL28604832 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1331942 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL240402 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL28641702 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL842 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL725546 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1332229 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3417188 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10896997 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL6889857 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028137-B2 | Mutant islet amyloid polypeptides with improved solubility and methods for using the same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3827813-A1 | MAGNESIUM COMPOSITIONS FOR MODULATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF INSULIN, AND INJECTION SITE PAIN | ELI LILLY AND CO. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3811968-A1 | INSULIN FORMULATIONS FOR RAPID UPTAKE | ELI LILLY AND CO. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-2838506-B1 | MAGNESIUM COMPOSITIONS FOR MODULATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF INSULIN, AND INJECTION SITE PAIN | LILLY CO ELI (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3372238-B1 | INSULIN FORMULATIONS FOR RAPID UPTAKE | LILLY CO ELI (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20190352356-A1 | MUTANT ISLET AMYLOID POLYPEPTIDES WITH IMPROVED SOLUBILITY AND METHODS FOR USING THE SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3372238-A1 | INSULIN FORMULATIONS FOR RAPID UPTAKE | Eli Lilly and Company (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2018144671-A1 | MUTANT ISLET AMYLOID POLYPEPTIDES WITH IMPROVED SOLUBILITY AND METHODS FOR USING THE SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-2403520-B1 | INSULIN FORMULATIONS FOR RAPID UPTAKE | LILLY CO ELI (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9399065-B2 | Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin | BIODEL INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2209528-A1 | RAPID ACTING INJECTABLE INSULIN COMPOSITIONS | Biodel, Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| US-20090192075-A1 | Amylin Formulations | BIODEL INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090137455-A1 | RAPID ACTING AND LONG ACTING INSULIN COMBINATION FORMULATIONS | BIODEL INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009048945-A1 | RAPID MUCOSAL GEL OR FILM INSULIN COMPOSITIONS | BIODEL, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009048959-A1 | RAPID ACTING INJECTABLE INSULIN COMPOSITIONS | BIODEL, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008124522-A2 | AMYLIN FORMULATIONS | BIODEL, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080248999-A1 | AMYLIN FORMULATIONS | BIODEL INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080096800-A1 | RAPID MUCOSAL GEL OR FILM INSULIN COMPOSITIONS | BIODEL, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080090753-A1 | insulin, a dissolution agent (actic acid, citric acid, maleic, adipic acid) and a zinc chelator(EDTA, EGTA, trisodum citrate etc.) to enhance uptake and transport of the insulin through epithelial cells as compared to insulin in combination with a zinc chelator and HCl | BIODEL, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080085298-A1 | Rapid Mucosal Gel or Film Insulin Compositions | BIODEL, INC. | 2008-04-10 | — | — | US | disclosed |